Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

[Genetics and angiogenesis: the example of von Hippel-Lindau disease].

Richard S, Ladroue C, Gad S, Giraud S, Gardie B; Réseau national maladie de VHL et prédispositions héréditaires au cancer du rein de l'Institut national du cancer (INCa).

Bull Cancer. 2007 Jul;94 Spec No:S170-9. Review. French.

PMID:
17846002
3.

Ocular von Hippel-Lindau disease: clinical update and emerging treatments.

Wong WT, Chew EY.

Curr Opin Ophthalmol. 2008 May;19(3):213-7. doi: 10.1097/ICU.0b013e3282fb7c04. Review.

4.

Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Liang X, Shen D, Huang Y, Yin C, Bojanowski CM, Zhuang Z, Chan CC.

Ophthalmology. 2007 Jan;114(1):147-56. Epub 2006 Oct 27.

5.

[Von Hippel-Lindau disease].

Takahashi K, Iida K, Chihara K.

Nihon Rinsho. 2006 Sep 28;Suppl 3:351-4. Review. Japanese. No abstract available.

PMID:
17022562
6.

von Hippel-Lindau syndrome.

Chou A, Toon C, Pickett J, Gill AJ.

Front Horm Res. 2013;41:30-49. doi: 10.1159/000345668. Epub 2013 Mar 19. Review.

PMID:
23652669
7.

VHL and HIF signalling in renal cell carcinogenesis.

Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP.

J Pathol. 2010 Jun;221(2):125-38. doi: 10.1002/path.2689. Review.

PMID:
20225241
8.

William G. Kaelin Jr. and Gregg L. Semenza receive the 2012 ASCI/Stanley J. Korsmeyer Award.

Claiborn K.

J Clin Invest. 2012 Apr;122(4):1136-7. No abstract available.

9.

Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.

Oncotarget. 2012 Nov;3(11):1472-82.

11.

Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease.

Wittström E, Nordling M, Andréasson S.

Ophthalmic Genet. 2014 Jun;35(2):91-106. doi: 10.3109/13816810.2014.886265. Epub 2014 Feb 20.

PMID:
24555745
12.

Kidney cancer: Programmed death ligand 1 regulation in ccRCC.

Stone L.

Nat Rev Urol. 2016 Feb;13(2):65. doi: 10.1038/nrurol.2016.2. Epub 2016 Jan 12. No abstract available.

PMID:
26754191
13.

HIFing the brakes: therapeutic opportunities for treatment of human malignancies.

Garcia JA.

Sci STKE. 2006 May 30;2006(337):pe25. Review.

PMID:
16738063
15.

Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.

Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM.

Biochim Biophys Acta. 1996 Mar 18;1242(3):201-10. Review. No abstract available.

PMID:
8603073
16.

Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer.

Shuin T, Kondo K, Ashida S, Okuda H, Yoshida M, Kanno H, Yao M.

Contrib Nephrol. 1999;128:1-10. Review. No abstract available.

PMID:
10597373
17.

Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma.

Wang Y, Abu-Asab MS, Shen D, Zhuang Z, Chew EY, Chan CC.

Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1319-27. doi: 10.1007/s00417-014-2660-0. Epub 2014 May 24.

PMID:
24859386
18.

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot S, Baud V, Mejean A, Mole DR, Richard S, Eggermont AM, Albiges L, Mami-Chouaib F, Escudier B, Chouaib S.

Eur Urol. 2016 Oct;70(4):623-632. doi: 10.1016/j.eururo.2015.11.029. Epub 2015 Dec 23.

PMID:
26707870
19.

A novel mutation in the VHL gene in a Chinese family with von Hippel-Lindau disease.

Wu X, Chen L, Zhang Y, Xie H, Xue M, Wang Y, Huang H.

BMC Med Genet. 2018 Nov 26;19(1):204. doi: 10.1186/s12881-018-0716-4.

20.

The HIF and other quandaries in VHL disease.

Tarade D, Ohh M.

Oncogene. 2018 Jan 11;37(2):139-147. doi: 10.1038/onc.2017.338. Epub 2017 Sep 18. Review.

PMID:
28925400

Supplemental Content

Support Center